Monte Rosa Therapeutics Price Target Maintained With a $11.00/Share by Wedbush
Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics Analyst Ratings
Buy Rating Affirmed: Anticipated Catalysts and Undervaluation Set to Boost Monte Rosa Therapeutics
TD Cowen Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)
Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Maintains $16 Price Target
Monte Rosa Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics Analyst Ratings
Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $11 Price Target
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Aerovate Therapeutics (AVTE)
Buy Rating Affirmed for Monte Rosa Therapeutics Amidst Promising Drug Pipeline and Stable Financials
UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating
Monte Rosa Therapeutics (GLUE) Gets a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
Wells Fargo Gives a Buy Rating to Monte Rosa Therapeutics (GLUE)
Promising Clinical Progress and Strategic Milestones Bolster Buy Rating for Monte Rosa Therapeutics
Monte Rosa Therapeutics (GLUE) Receives a Buy From Piper Sandler
Monte Rosa Therapeutics Analyst Ratings
Wedbush Starts Monte Rosa Therapeutics With Outperform Rating, $11 Price Target